NASDAQ
Oncolytics Biotech Inc. (ONCY)
♥ 356 Thanks from members
Oncolytics Biotech Inc. (ONCY) exhibits mixed sentiment, driven by promising clinical alignments with the FDA for pelareorep in colorectal and anal cancers, balanced against mounting net losses, low cash reserves, and explicit going concern warnings.